|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 22, 2017 ) According to the report Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market, published by Market Data Forecast, the market is projected to reach USD 1906 Billion by 2021, at a CAGR of 14.3% from 2016 to 2021.
Nuclear medicines are fundamentally drugs that contain radioactive components for radionuclide-transmitting ionizing radiations. Their core application lies in the determination and treatment of different ailments that ordinary prescriptions fail to accomplish. Radiopharmaceuticals are extraordinary as they are utilized to directly target particular organs in the body where the medication can transmit radiations. These radiations are then caught by gamma cameras put in vicinity of the patient. The radiation measurement in these drugs is kept as low as conceivable to avoid the reactions of radiation exposure.
Radiopharmaceuticals are controlled inside a patient's body through various courses, including oral, inhalation, or infusion. This to a great extent relies upon the idea of the components being utilized and the organ that is targeted. Radiopharmaceuticals can help in the analysis of the blood stream in cerebrum cells, heart pumping rate and working system of kidney cells. Radiopharmaceuticals are utilized as a part of the diagnosis of mental diseases, such as Parkinson's disease and Alzheimer's, and additionally help pinpoint the location of tumors or minute bone fractures in a body.
Get a comprehensive overview of the Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/
Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: Drivers & Restraints
Increasing incidence of chronic diseases such as cancer and cardiac ailments, advancements in technology, increasing demand for SPECT and PET applications along with the growing public awareness for healthcare are fuelling the growth of the market. Further, new developments such as Integration of X ray tomography (CT) into SPECT provide an excellent diagnostic tool in medical imaging and are considered to be a driving factor for the growth of the market. Strict regulatory framework poses a potential hurdle to translational research and clinical investigations. Reimbursement issues are also blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are the key factors restraining the Asia-Pacific nuclear medicine Radioisotopes market.
Get accurate market forecast and analysis on the Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/request-sample
Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: Segmentation
By Type
● Diagnostic Radioisotopes
o SPECT
● Technetium-99m
● Thallium-201
● Gallium-67
● Iodine-23
● Others
o PET
● Fluorine-18
● Rubidium-82
● Others
● Therapeutic Radioisotopes
o Beta Emitters
● Iodine-131
● Yttrium-90
● Samarium-153
● Rhenium-186
● Lutetium-177
o Alpha Emitters
● Radium-223
o Brachytherapy
● Cesium-131
● Iodine-125
● Palladium-103
● Iridium-192
By Application
● Cardiology
● Lymphoma
● Thyroid
● Neurology
● Oncology
● Others
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization. Get customization at: http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/customize-report
Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: Overview
Radiopharmaceuticals are pharmaceutical definitions involving radioactive isotopes that are utilized as a part of determination and therapeutics. They are simple and little substances that contain a radioactive substance that is utilized as a part of the treatment of disease and cardiovascular and neurological disorders.
The ordinary chemotherapy techniques are being replaced by more helpful therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. Additionally, it helps doctors amid diagnosis, as well as acts as an advantageous and more secure option for patients when compared with X-Rays and other radiation imaging gadgets. Radiopharmaceuticals, otherwise called atomic drugs, are utilized in applications like lymphoma and bone metastasis.
Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: Region-wise Outlook
On the basis of geography, the Asia-Pacific Market is segmented into various regions namely, India, China, Japan and South Korea. India and China hold a potential market for radioisotope due to growing healthcare sector and increasing demand for different radioisotopes in various treatments and applications.
Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: Key Players
Some of the key players influencing the Asia-Pacific nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
